硝普钠联合重组人尿激酶原对老年急性STEMI行PCI无复流患者的效果观察  

Effect observation of sodium nitroprusside combined with recombinant human prourokinase on no-reflow in elderly patients with acute STEMI after PCI

作　　者：王国峰 WANG Guo-feng(Department of Cardiology,Beipiao Central Hospital,Beipiao 122100,China)

机构地区：[1]辽宁省北票市中心医院心血管内科,122100

出　　处：《中国现代药物应用》2022年第11期86-89,共4页Chinese Journal of Modern Drug Application

摘　　要：目的 探讨硝普钠联合重组人尿激酶原对老年急性ST段抬高型心肌梗死(STEMI)行经皮冠状动脉介入治疗(PCI)无复流患者的效果。方法 92例老年急性STEMI行PCI无复流患者,随机分为参照组与治疗组,每组46例。两组PCI术前常规用药,对照组采用硝普钠治疗,治疗组采用硝普钠联合重组人尿激酶原治疗。对比两组治疗前后校正的TIMI帧数(cTFC)、治疗后TIMI血流分级、临床疗效、心血管不良事件发生情况。结果 治疗前,两组患者的cTFC比较差异无统计学意义(P>0.05);治疗后,两组cTFC均明显低于治疗前,治疗组c TFC(28.24±4.47)帧明显低于参照组的(34.68±4.56)帧,差异具有统计学意义(P<0.05)。治疗后,治疗组TIMI 3级占比89.13%明显高于参照组的71.74%,而TIMI≤2级占比10.87%显著低于参照组的28.26%,差异具有统计学意义(P<0.05)。治疗组患者的总有效率为95.65%,显著高于参照组的82.61%,差异具有统计学意义(P<0.05)。治疗组患者心血管不良事件发生率为8.70%(4/46),低于参照组的23.91%(11/46),差异具有统计学意义(χ^(2)=3.903, P<0.05)。结论 经硝普钠联合重组人尿激酶原治疗老年急性STEMI行PCI无复流患者,可明显改善患者的心肌灌注水平,临床疗效明显,安全性更高。Objective To discuss the effect of sodium nitroprusside combined with recombinant human prourokinase on no-reflow in elderly patients with acute ST-segment elevation myocardial infarction(STEMI) after percutaneous coronary intervention(PCI). Methods A total of 92 patients with acute STEMI and no-reflow after PCI were randomly divided into reference group and treatment group, with 46 cases in each group. Both groups were treated with conventional medication before PCI. The reference group was treated with sodium nitroprusside,and the treatment group was treated with sodium nitroprusside combined with recombinant human prourokinase.Both groups were compared in terms of corrected TIMI frame count(cTFC) before and after treatment, TIMI flow classification after treatment, clinical efficacy, and occurrence of cardiovascular adverse events. Results Before treatment, there was no statistically significant difference in cTFC between the two groups(P>0.05). After treatment, the cTFC in both groups was significantly lower than that before treatment in this group, and the cTFC(28.24±4.47) frames in treatment group was significantly lower than(34.68±4.56) frames in reference group.All the differences were statistically significant(P<0.05). After treatment, the proportion of TIMI grade 3 in the treatment group was 89.13%, which was significantly higher than 71.74% in the reference group;while the proportion of TIMI ≤ grade 2 was 10.87%, which was significantly lower than s 28.26% in the reference group;all the differences were statistically significant(P<0.05). The total effective rate in the treatment group was 95.65%,which was significantly higher than 82.61% in the reference group, and the difference was statistically significant(P<0.05). The incidence of cardiovascular adverse events in the treatment group was 8.70%(4/46), which was lower than 23.91%(11/46) in the reference group, and the difference was statistically significant(χ^(2)=3.903,P<0.05). Conclusion Sodium nitroprusside combined with recombinant human prou

关 键 词：急性ST段抬高型心肌梗死 经皮冠状动脉介入治疗 硝普钠 重组人尿激酶原 无复流 老年 

分 类 号：R542.22[医药卫生—心血管疾病]